Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Last trade$28.55
Day change+$0.68 (+2.44%)
Day range$26.86 – $29.16
Volume1,226,745
Market cap$4.51B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.51B
Price / earnings
—
Price / book
25.6×
Price / sales
15.14×
EV / sales
16.01×
EV / EBITDA
-145.14×
Profitability
Earnings per share
-$0.44
Return on assets
-10.33%
Return on equity
-40.06%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.9×
Current ratio
3.97×
Quick ratio
3.87×
Cash ratio
0.76×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$8.82M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ADPT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$83.9M
$71.55M
$70.87M
$71.68M
$93.97M
$58.88M
$52.44M
$47.46M
Cost of revenue
$20.36M
$20.17M
$18.71M
$18.22M
$18.59M
$18M
$16.98M
$18.05M
Gross profit
$63.54M
$51.39M
$52.17M
$53.46M
$75.39M
$40.88M
$35.46M
$29.41M
Selling, general and administrative
$45.36M
$47.58M
$47.33M
$44.04M
$41.43M
$41.36M
$40.45M
$39.63M
Research and development
$18.64M
$19.15M
$23.62M
$21.76M
$23.67M
$24.13M
$24.2M
$23.19M
Total operating expenses
$64M
$67.16M
$71.37M
$66.23M
$65.1M
$65.92M
$65.07M
$63.25M
Operating income
-$457K
-$15.77M
-$19.21M
-$12.77M
$10.29M
-$25.04M
-$29.6M
-$33.84M
Interest expense
-$503K
-$2.69M
-$2.89M
-$2.95M
-$2.97M
-$2.95M
-$2.91M
-$2.95M
Income before taxes
$2.81M
-$39.94M
-$20.02M
-$13.58M
$9.55M
-$25.59M
-$29.83M
-$33.72M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
$2.81M
-$39.94M
-$20.02M
-$13.58M
$9.55M
-$25.59M
-$29.83M
-$33.72M
Net income attributable to common shareholders
$2.81M
-$39.79M
-$20.03M
-$13.58M
$9.55M
-$25.61M
-$29.85M
-$33.69M
EBITDA
$3.15M
-$12.08M
-$15.37M
-$8.58M
$14.7M
-$20.53M
-$24.87M
-$29.39M
Basic earnings per share
$0.02
-$0.25
-$0.13
-$0.09
$0.06
-$0.17
-$0.20
-$0.23
Diluted earnings per share
$0.02
-$0.25
-$0.13
-$0.10
$0.06
-$0.17
-$0.20
-$0.23
Recent news
Company coverage with links to the original publishers.
Summit Therapeutics received an FDA Complete Response Letter (CRL) for ivonescimab plus chemotherapy in NSCLC patients, declining approval due to insufficient evidence of effectiveness. While the HARMONi trial met its progression-free survival endpoint, it failed to demonstrate statistically significant overall survival benefit. The decision represents a major regulatory setback, delaying the company's first marketed product and U.S. commercial revenues.
Altimmune reported a Q3 2026 loss of 15 cents per share, missing consensus estimates by one cent. R&D expenses surged 80.6% to $27 million due to ongoing pemvidutide clinical studies. The company has $480 million in cash expected to fund operations into 2029. Stock declined 17% following the announcement due to concerns over rising development costs and funding uncertainty for the planned phase III AUD program.
Aura Biosciences completed enrollment and dosing in its phase III CoMpass study evaluating bel-sar for early choroidal melanoma treatment. Top-line data is expected in the second half of 2027. If successful, bel-sar could become the first FDA-approved frontline vision-preserving therapy for this indication. The company is also exploring bel-sar for choroidal metastases and ocular surface cancers, with updates expected in Q1 2027. AURA shares have risen 39.6% year-to-date.
Zoetis announced USDA approval for Cytopoint Plus, a monoclonal antibody therapy providing 75 days of relief from allergic itch in dogs. The extended dosing interval is approximately 1.5 times longer than existing mAb options, expanding Zoetis' canine dermatology portfolio alongside Cytopoint, Apoquel, and Apoquel Chewable. Market uptake will depend on pricing, veterinary recommendations, and real-world performance.
Beam Therapeutics reported positive top-line results from its BEACON study for risto-cel, a gene-editing therapy for sickle cell disease, achieving primary efficacy and safety endpoints with patients demonstrating freedom from severe vaso-occlusive crises for at least 12 consecutive months. The company plans to submit a biologics license application to the FDA by end of 2026, potentially marking the first commercial product approval for a base-editing therapy. Despite the encouraging clinical results, BEAM shares declined 7% following the announcement, likely due to concerns over weaker third-quarter results and profit-taking.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.